Study on protective effect of vanillic acid from Astragalus membranaceus on hypertensive cardiac remodeling based on network pharmacology screen.
10.19540/j.cnki.cjcmm.20191022.402
- Author:
Bo-Yang WANG
1
;
Tian-Long LIU
2
;
Jing LIU
2
;
Ming-Jie ZHANG
2
;
Jian-Jun SUN
2
;
Xiao-Lei LIU
3
;
Rui-Lian MA
2
Author Information
1. Orthopaedic District B, the Affiliated Hospital of Inner Mongolia Medical University Hohhot 010030, China.
2. Pharmacy Department, the Affiliated Hospital of Inner Mongolia Medical University Hohhot 010030, China.
3. Pharmacology Department, Inner Mongolia Medical University Hohhot 010110, China.
- Publication Type:Journal Article
- Keywords:
Astragalus membranaceus;
cardiac remodeling;
network pharmacology;
protective effect;
vanillic acid
- MeSH:
Angiotensin II;
Animals;
Astragalus propinquus/chemistry*;
Heart;
Hypertension/genetics*;
Mice;
Protective Agents/pharmacology*;
Vanillic Acid/pharmacology*;
Ventricular Remodeling/genetics*
- From:
China Journal of Chinese Materia Medica
2020;45(2):367-373
- CountryChina
- Language:Chinese
-
Abstract:
To identify and verify the active ingredients from Astragalus membranaceus on hypertensive cardiac remodeling based on network pharmacology and heart RNA-sequencing data. The monomers of A. membranaceus and their intervention target database were established by using network pharmacology. The genes associated to cardiac remodeling were then screened by analyzing cardiac RNA-sequencing data. An overlap between genes related to cardiac remodeling and targets of ingredients form A. membranaceus was collected to obtain monomers with protective effect on hypertensive cardiac remodeling. Angiotensin Ⅱ(AngⅡ)-induced mouse cardiac remodeling model was used to validate the protective effect of active ingredients from A. membranaceus on hypertensive cardiac remodeling. Finally, a total of 81 monomers and 1 197 targets were enrolled in our database. Mouse RNA-sequencing data showed that 983 genes were significantly up-regulated and 465 genes were down-regulation in myocardial tissues of the cardiac remodeling mice as compared with blank group mice, respectively. Ninety-two genes were found via overlapping between genes related to cardiac remodeling and targets, involving 59 monomers from A. membranaceus. Further research found that vanillic acid(VA) could intervene 27 genes associated with hypertensive cardiac remodeling, ranking top 1. Meanwhile, VA could significantly inhibit AngⅡ-induced increase in ratio of heart weight to body weight and heart weight to tibial length, ANP and BNP mRNA levels in myocardial tissues, myocardial tissue damage, cardiac fibrosis level and cardiac hypertrophy level in vivo. Those results showed that network pharmacology screen-based VA has protective effect on AngⅡ-induced cardiac remodeling.
